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Abstract
Purpose of Review Solid organ transplantation is limited by lack of suitable donor organs. Older and comorbid organs are
frequently discarded on the basis that they will not withstand the overall process—principally the degree of ischemia reperfusion
injury associated with preservation and transplantation. Interventions to prevent injury and promote regeneration are badly
needed. Recent stem cells of multiple types including mesenchymal stem cells (MSCs) and adipose-derived regenerative cells
(ADRCs) have been demonstrated to protect against tissue injury in multiple models relevant to transplantation.
Recent Findings Recent studies have improved our understanding of the multiple mechanisms underlying these beneficial effects
including immunomodulatory and anti-inflammatory actions. Evidence suggests extracellular vesicular transfer of therapeutic
factors, such as Sox9, cytokines, IL-17A, CCR2, and S1P has a key role in these effects.
Summary Several novel approaches such as stress treatments, culture techniques, and exogenous chemical manipulation show
significant promise in improving the efficacy of stem cell populations in preventing tissue injury. There is even the possibility to
harness the body’s own sources of such cells through interventions such as point-of-care fat modulation or mobilization of
endogenous bone marrow-derived cells. The many unanswered questions and barriers to translating this promising technology to
clinical transplantation are discussed.
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Introduction
Solid organ transplantation has revolutionized the treat-
ment of organ failure. Immunological barriers have pro-
gressively reduced, but the challenge of inadequate donor
organ supply has grown with increasing demand [1]. This
has led to escalating use of older/comorbid donor organs
[2]. Aside from intrinsic increased cellular senescence [3],
such organs do not tolerate the injurious processes associ-
ated with removal, storage, and transplantation as well as
traditionally used organs from younger donors [4] partic-
ularly, ischemia reperfusion injury (IRI) [5].
Regenerative medicine approaches to organ transplantation
have initially focused on the generation of functioning neo-
tissue, highlighted widely as the main potential benefit of
pluripotent stem cells. This approach spans artificial organ
construction, the engineering of bioactive, organ-like tissue
[6], and the use of infused stem cells [7]. Examples of such
tissue successfully generated for clinical use do exist [8] for
relatively simpler tubular structures but translation to therapy
fields currently served by solid organ transplantation has been
slow and frequently remains at the preclinical stage [9].
This has led to a switch in focus to addressing the regener-
ative capacity of organs already available—including those
currently declined for solid organ transplantation because of
predicted poor function post-transplantation. This approach
focuses on protecting organs from peri-transplantation injury
(principally IRI) and enhancing tissue regeneration after trans-
plantation. Stem cells provide a promising source of protec-
tive and regenerative properties; however, there are many dif-
ferent forms of “stem cells” and accurate characterization and
functionality can be complex. Pluripotency, multipotency, or
oligopotency are clearly essential to form functioning neo-
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tissue but such characteristics may be less critical to the ability
to influence other tissue to survive injury and regenerate. The
wide variety of stem cell subtypes currently used in organ
regeneration is illustrated in Table 1. A complex yet promising
regenerative tool advances have been made in longevity and
efficacy of infused stem cell therapy as well as an increased
understanding of signaling pathways and secreted factors
associated with stem cell-induced transplantation repair.
These and new approaches to mobilizing endogenous stem
cells in transplant recipients are emerging and are de-
scribed in this review.
Stem Cell Administration Protects Against IRI
The efficacy of infused mesenchymal stem cells (MSCs) of
various origins in limiting IRI across multiple preclinical
models is well established. Several such models have demon-
strated this effect in rodent kidney [10–12] and a multicellular
suspension of adipose-derived regenerative cells (ADRCs)
with a substantial MSC component has exhibited similar prop-
erties [13]. Analogous observations have been described in
liver models [14] and while less relevant to transplantation,
similar cell types have been widely applied to the inhibition of
ischemia reperfusion in myocardial infarction [15] and stroke
[16]. This work builds on the identification of a key pathway
which appears conserved across IRI pathways in different
organs—the accumulation of succinate under conditions of
ischemia followed by oxygen-free-radical-mediated inflam-
matory damage on reperfusion [17•]. Harnessing this efficacy
and translating it to clinical transplantation is a key challenge.
Improving the Efficacy and Survival of Stem
Cells in IRI Therapy
The lifespan of mesenchymal stem cells is short when admin-
istered to models of IRI, typically < 4% detectable by day 4
post-administration [18], potentially due to the harsh micro-
environment created by ischemia reperfusion (IR) [19].
Improving stem cell resilience and survival could improve
the efficacy and potency of the administered cells, perhaps
reducing side effects related to cell dosage. Current techniques
to fortify stem cells for clinical use include culture precondi-
tioning and stem cell genetic transduction.
A recently devised method to precondition MSCs utilizes
heat shock. Qiao et al. heated MSCs in a 42 °C water bath 2 h
before treating rats suffering from hepatic IRI. They found that
heat shock pre-treated MSCs experienced less apoptosis than
non-treated MSCs and further discovered that pre-treated
MSCs coped in a high oxidative stress environment of hydro-
gen peroxide by increasing levels of autophagy. Furthermore,
the authors demonstrated that an increase in autophagy was
via the p38MAPK/mTOR signaling pathway, since a
p38MAPK inhibitor removed the effect. Finally, it was dem-
onstrated that MSCs pre-treated with heat shock before ad-
ministration to hepatic IR rats improved liver function, histo-
logical scores, and increased levels of proliferating cells com-
pared to treatment with non-preconditioned MSCs, highlight-
ing the importance of MSC resilience in the IRI microenvi-
ronment [20].
3D (versus 2D) cultured stem cells have also been found to
enhance stem cell survival and efficacy in IR models of both
hepatic and renal injury. 3D cultured cells exhibit an increased
Table 1 Stem cell diversity
Class of stem cell Potency Clinical administration
Tissue-specific stem cells (Somatic-derived)
Blood-derived stem cells multipotent Cultured expansion necessary
Adipose derived regenerative cells pluripotent Directly transplantable
Bone marrow derived cells pluripotent Cultured expansion necessary
Endometrial regenerative cells pluripotent Directly transplantable
Induced pluripotent stem cells (Somatic-engineered) pluripotent Cultured expansion necessary
Mesenchymal stem cells (Stroma-derived)
Bone marrow derived mesenchymal stem cells multipotent Cultured expansion necessary
Adipose derived mesenchymal stem cells multipotent Cultured expansion necessary
Endothelial stem cells multipotent Cultured expansion necessary
Dental pulp stem cells multipotent Cultured expansion necessary
Embryonic stem cells (Embryo-derived)
Morula derived stem cells totipotent Cultured expansion necessary
Blastocyst derived stem cells pluripotent Cultured expansion necessary
Umbilical derived stem cells pluripotent Cultured expansion necessary
Extraembryonic stem cells multipotent Cultured expansion necessary
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anti-inflammatory phenotype and exhibit a higher expression
of angiogenesis genes. This anti-inflammatory effect may be
explained by upregulated levels of ZC3H12A RNase, which
destabilizes mRNAs of pro-inflammatory cytokines and
chemokines like IL-6, CXCL1, CXCL2, and CXCL3 [21].
In addition, MSCs from a 3D culture were smaller in size
which may allow them better penetration through the micro-
vasculature of the lungs when administered intravenously, and
in effect lower doses to be administered. In addition, multiple
publications have documented improved angiogenic and anti-
apoptotic effects of 3D versus 2D cultured cells and have
demonstrated enhanced survival supporting the claim that
they are less susceptible to the harsh IR environment [21, 22].
Since MSC-induced expansion of regulatory immune cells in
IRI is believed to be an important component of their pro-
regenerative effect, group Bai et al. pre-treated cultured MSCs
in a regulatory cell attractant, cytokine IL-17A, before injection
in a mouse model of renal IRI, demonstrating significantly re-
duced renal damage compared to non-treated MSC controls
[23••]. The increase in splenic and renal T-regs demonstrated,
occurred through a cyclooxygenase-2/prostaglandin E2 (COX-
2/PGE2)-dependent pathway, as blockage of COX-2 reversed
the protective effect and reduced levels of T-regs. The involve-
ment of COX-2 and of PGE2, (a hormone upregulated by COX-
2) in T-reg production is likely due to the PGE2 effect of inducing
differentiation of T cells to regulatory T cells [24]. A particularly
interesting observation about IL-17A pre-treatment, not evident
for other cytokineMSC pre-treatments such as IFNγ [25•] is that
IL-17A enhanced downstream immunosuppressive effectors
without inducing upregulation of histocompatibility molecules
(MHC I and MHC II) and maintained normal MSC
morphology—both of which could potentiate immunogenicity
and harmful MSC properties.
Genetic modification of pluripotent stem cells in
humans has been possible and progressively refined since
the 1990s [26]. More recently, this approach has been ap-
plied to improve stem cells’ ability to ameliorate IRI.
Administration of amniotic fluid stem cells expressing up-
regulated vascular endothelial growth factor (VEGF), via a
lentiviral vector expressing VEGF, reduced tubular cell
necrosis and improved renal function compared to treat-
ment with non-transduced stem cells in a rat IRI model.
Additionally, transduced stem cells had a mitogenic effect
on tubular cells, increased the levels of T-regs and de-
creased pro-inflammatory M1 macrophage infiltration
[27]. Similarly, bone marrow MSCs transduced to increase
anti-oxidant, heme-oxygenase-1 expression, were more re-
silient to the IR environment surviving longer, decreasing
the number of tubular epithelial cells in the G0/G1 (resting/
interphase) stage, and significantly increasing proliferating
cells [28]. However, although gene modulation appears to
be an attractive tool, safety issues remain a fundamental
issue.
Advances in Understanding Organ Stem Cell
Therapeutic Mechanisms
While efficacy against IRI has been known for more than
10 years, the mechanism of stem cell action remains poorly
understood [29, 30]. A consistent theme in recent studies sug-
gests that stem cells exert a paracrine effect transferring cyto-
kines and extracellular vesicles (EVs) to neighboring cells,
and in the context of IRI, initiate repair through the limitation
of fibrotic progenitors, inhibition of cell death, and the reduc-
tion of inflammation. Zhu and colleagues show that injected
EVs, exosomes, extracted from adipose-derived stem cells
(ADRCs) in a renal IRI mousemodel improved renal outcome
by tubular epithelial cell activation of transcription factor,
SRY (sex determining region Y)-box 9 (Sox9) [31••]. Sox9
as a reparative factor is consistent with evidence that shows
Sox9 promotion of tubular epithelial cell proliferation during
embryonic development; and supports Zhu et al.’s additional
studies which indicated an abrogation of tubular epithelial cell
proliferation after administration of Sox9 inhibitors in the IRI
model. ADRC exosomal activation of Sox9 may also reduce
progression to chronic kidney disease through simultaneous
upregulation of Sox9 and downregulation of transforming
growth factor (TGF)-β1 potentially avoiding upregulation of
genes involved in building extracellular matrix and developing
fibrosis [32]. Sox9 may be a key regenerative mechanism in
other organs as Sox9-dependant processes are also present dur-
ing liver repair [33]. However, whether the Sox9 gene can be
administered as a therapeutic remains unclear, as a high Sox9
expression is correlated with glomerulosclerosis and liver fibro-
sis [34]. Mesenchymal stem cells (MSCs) were also associated
with elevated levels of transcription factors, AP-1, STAT3, and
NF-kB. These factors may serve a reparative role by priming
resident cells to enter the cell cycle, promoting proliferation and
ultimately regeneration of injured tissue [35] (Fig. 1).
Stem cell extracellular vesicle transfer of specificity protein
1 (SP1) and its downstream regulators of necroptosis have
been shown to be another paracrine mechanism in IRI inhibi-
tion. Necroptosis, like apoptosis, is a form of regulated cell
death; however, unlike apoptosis, necroptosis is initiated by
inflammation-related cellular damage that externally stimu-
lates TNF receptors in the absence of active caspases [36,
37]. SP1 is a transcription factor that upregulates sphingosine
kinase-1 (SK1) which enzymatically catalyzes the formation
of sphingosine-1-phosphate (S1P). S1P is a bioactive
sphingolipid metabolite that promotes cell growth and surviv-
al by acting on several G protein-coupled S1P receptors which
upregulate anabolic and survival pathways [38, 39].
Delivering SP1-containing extracellular vesicles derived from
human-induced pluripotent stem cell-derived MSCs (hiPSC-
MSCs) to a rat IR model improved renal function, histological
features, and reduced kidney necroptosis as established by
annexin V/PI positivity tests [40••]. Co-administration of
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SP1 or SK1 inhibitors increased necroptosis and abolished the
renoprotective effects in the animal model. Analogously, SK
and S1P-dependant inhibition of necroptosis is also a demon-
strated MSC mechanism in liver IRI treatment [41].
In addition to inhibiting necroptosis, stem cells may also
discourage cell death by inhibiting apoptosis. Stem cell pro-
motion of mitogen-activated protein kinases (MAPK), which
potentiate downstream signaling leading to apoptosis has been
proposed as a potential stem cell induced pathway, especially
given that bone marrow-derived stem cells have been shown to
reduce the phosphorylation of ERK and p38, both vital signal-
ing proteins inMAPK transduction [42]. However, further stud-
ies confirming stem cell downstream effects in inhibiting cell
death, either through apoptosis or necroptosis are required.
Reducing regulated cell death may improve residual organ
function but being able to modulate the immune systems’
response to IRI may provide greater benefits on both retaining
residual function and on long-term organ survival by
disrupting positive feedback of sensitizing events. Stem cell
immunomodulation has been extensively researched, in par-
ticular, stem cell-induced expansion of T-regs is proposed as a
key therapeutic mechanism [43]. T-regs are known to suppress
inflammatory functions of cells such as CD8+ T cells, macro-
phages, dendritic cells, natural killer cells, and B cells. In the
context of renal IRI, it is reported that T-regs downregulate
IFNγ production by local T cells, reducing the overall kidney
inflammatory insult [44]. In a recently studied IRI mouse




Fig 1 New concepts in stem cell therapy of organ graft IRI repair.
Summary of recent advances in stem cell IRI organ therapy includes a
progress in increasing cell resilience though culture techniques which
incorporates mechanical stimulation of heat shock and 3D culturing as
well as through stimulation with cytokine IL-17A. In addition, benefits
are being made to increase stem cell therapeutic potency in an IR
environment by gene transduction with VEGF and heme-oxygenase-1
(HO-1). b Recent advances in therapeutic stem cell mechanisms have
spanned signaling pathways that reduce fibrosis, necroptosis/apoptosis,
and inflammation. Notably, developmental gene, Sox9, specificity
protein 1 (SP1), part of the necroptosis pathway, and regulatory T-cells
(T-regs) play significant roles in stem cell IR amelioration. c An
alternative to exogenous administration of stem cells, which has
potential side-effects, methods have progressed to mobilize endogenous
mesenchymal stem cells (MSCs) from transplant recipient’s own
regenerative tissue (bone marrow-derived). Mobilization methods
include mechanical stimulation such as low-level laser therapy as well
as administration of stem cell proliferative factors, growth colony-
stimulating factor (G-SCF)
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significant increase in splenic T-regs which is proposed to
have improved the renal IRI outcome by potentiating a de-
crease in CD4+ T cells, CD8+ T cells, and inflammatory-
associated M1 macrophages levels while increasing levels of
regulatory M2-type macrophages [45]. Other potential mech-
anisms through which T-regs support organ preservation in
IRI include metabolic interference, cytolysis, and targeting
of antigen-presenting cells [46, 47]. Multiple clinical studies
modulating T-regs in the context of organ transplantation are
on-going and while not the principal end-point, evidence of an
improved preservation effect may emerge [46].
Another recent discovery implicating beneficial IRI immuno-
modulatory effects of stem cells was made by Shen et al. This
group uncovered that mesenchymal stem cells and their
exosomes contain particularly high levels of chemokine receptor
proteins—CCR1 andCCR2 [48••]. These receptors actively bind
and reduce the amounts of free CCL2. They went on to demon-
strate that the decrease in available CCL2 resulted in reduced
migration and activation of macrophages expressing the CCL2
cognate receptor, CCR2. Administration of MSC-derived
exosomes rich in CCR2 to a mouse model of IRI conferred
protection, and was reversed by a knockdown of CCR2 on
MSC-derived exosomes. This study thus provides a potentially
novel target for therapeutic studies in IRI and suggests that stem
cell-derived exosomes not only mediate cellular transfer of tran-
scription factors and microRNAs but also of protein receptors.
Another recent study links stem cell IRI modulation of the
complement pathway. C5a is a major regulator in inflamma-
tion and can potentiate NF-κB activation. NF-κB regulates the
transcription of many inflammatory genes and can serve as an
upstream activator of macrophages. Bone marrow-derived
MSCs administered in a mouse model of renal IRI significant-
ly suppressed C5a in serum and C5aR in kidney tissue. The
suppression of the C5a/C5aR-NF-κB pathway resulted in re-
duced macrophage activation and reduced secretion of mac-
rophage pro-inflammatory cytokines, TNF-α and IL-6, with
significant improvement in renal function [49].
Mechanistic data has paved the way for clinical trials in
stem cell therapy in organ preservation and indicates impor-
tant roles for reducing fibrosis, cell death, and inflammation.
However, new discoveries of stem cell-derived regenerative
factors and newly discovered stem cell targets of modulation
still leaves us well short of understanding the full scope of
stem cell’s potential beneficial effects including possible syn-
ergistic effects between multiple cell types.
Mobilizing Endogenous Stem Cells
in Transplant Recipients
Exogenous administration of cells carries the risk of infection,
immune-sensitivity, teratogenicity, microvascular thrombosis
as well as the possible logistical and cost issues associated
with administration. To address some of these concerns, sev-
eral groups have investigated methods to increase the produc-
tion and mobilization of stem cells from one’s own resident
stem cell populations. Rats treated with stem cell factor (SCF)
and granulocyte colony-stimulating factor (G-CSF) in renal
models of IRI were found to have increased mobilization of
endogenous stem cells, which homed to the injured kidney
and ameliorated IR through mechanisms associated with up-
regulation of angiogenic factor, VEGF and anti-oxidant factor,
hypoxia-inducible factor (HIF)-1alpha. Treated rats displayed
reduced kidney apoptosis and increased tubular repair [50].
However, as an IRI treatment, there is concern with systemic
administration of growth factors related to high bioactive ef-
fects which can lead to deleterious side-effects including tu-
morigenesis [51]. Additionally, evidence indicates that resi-
dent stem cells become depleted or dysfunctional with in-
creasing age, limiting this approach in older patients [52].
There may however be potential for this approach if stem cell
mobilization therapies can be rendered organ and/or signaling
pathway specific.
In a novel attempt to reduce injury from IR by recruitment
of endogenous stem cells, Tan et al. investigated
postconditioning kidneys with supplementary mechanical in-
jury insult in their rat model [53]. The postconditioning model
consisted of 3 cycles of 30 s of ischemia followed by 30 s of
reperfusion in a kidney which previously sustained 45 min of
ischemia followed by 7 min of reperfusion. Postconditioning
markedly reduced features of renal injury including kidney
necrosis, neutrophil infiltration, and cellular vacuolization,
and significantly reduced creatinine levels compared to non-
preconditioned rats [53]. Importantly, the Tan et al. group
illustrated that this techniquemobilized endogenous stem cells
as blood from preconditioned rats had increased levels of
CXCR4+ and CD34+ (haemopoietic) bone-derived stem
cells. They concluded that preconditioning regulated oxida-
tive stress and increased HIF-1alpha levels which then in-
creased stromal cell-derived factor expression, a stem cell at-
tractant, resulting in stem cell migration and homing to ische-
mic tissues [54, 55]. MacAllister et al. performed a similar
preconditioning technique in a trial of 406 live donor kidney
transplants. Though there was only mild improvement in glo-
merular filtration rate when compared to control, the trend of
graft functional improvement appeared promising and may be
greater in deceased donor transplantation where IRI is more
significant [56].
In an innovative attempt to mobilize resident stem cells,
Wang et al. used low-level laser therapy (LLT) treatment of
bone marrow in rats before renal IRI. By exposing both tibiae
to two episodes of 100 s each of LLT they significantly in-
creased bone marrow-derived stem cell infiltrates in the glo-
merulus and renal tubules but not in the peripheral blood.
Interestingly, rats undergoing LLT without IRI had elevated
levels of bone marrow-derived stem cells in the peripheral
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blood, indicating that injury status affected migration.
Notably, LLT-treated rats had significantly improved renal
function and kidney histology indicating the potential value
of LLT mobilized stem cells as an IRI therapy. They hypoth-
esized that LLT induces proliferation of bone marrow-derived
mesenchymal stem cells, which home to injured kidney tissue
and elicit repair [57•]. Promising as this seems, further studies
are required to understand if sufficient numbers of ameliora-
tive endogenous stem cells can be mobilized to have an effect
on larger human organs that have sustained clinically signifi-
cant tissue injury. There is also a potential limit in elderly or
physiologically unfit patients where the capacity of endoge-
nous stem cells to replicate may be significantly impaired.
Conclusion
Stem cells from diverse tissue sources have intrinsic therapeu-
tic properties that can be harnessed in organ repair and pres-
ervation. Though they impart their therapeutic properties
when administered to the harsh environment of IR-inflicted
organs, they can be fortified and administered at minimized
dosages through preconditioning and genetic modification to
extend the persistence and potency of their beneficial effects.
Our understanding of stem cell therapeutic mechanisms
remains limited; however, there is a general consensus that
they reduce inflammation and encourage repair and growth
[58, 59]. Research presented in this review indicates the im-
portance of extracellular vesicular transfer, the importance of
therapeutic factors that include signaling transducers, cytokines,
chemokine receptors, microRNAs, and RNAses; and clinical
studies confirm that stem cell-treated IR organs undergo a con-
siderable reduction of injury as determined by histological pa-
rameters and by significant improvement in organ measure-
ments of function.
We believe that for the purpose of organ protection and
reconditioning for transplantation, the therapeutic potential
of stem cell therapies is great. Two major obstacles to routine
clinical use are immunological barriers and the risks of ex-
vivo culture/expansion. To that end, autologous, point-of-
care-derived stem cell therapies, such as adipose-derived re-
generative cells (ADRCs) and endometrial regenerative stem
cells (women-only) are attractive. In the case of ADRCs, this
may be particularly fruitful as cells derived from adipose tis-
sue are characterized as containing > 500 times the levels of
MSCs as from cells derived from bone marrow [60–62].
ADRC use, combined with researched preconditioning tech-
nologies (such as IL-17A exposure) can potentially improve
persistence and efficacy without acquiring deleterious dosage
side effects related to teratoma development [63]. However,
pre-manipulation of stem cells can pose risks. Mori da Cuhna
et al. notes that beneficial effects of VEGF-transduced MSCs
were actually reversed and even caused a worsened IR out-
come when MSC expressed VEGF at high levels [27].
Since severe IRI leads to fibrosis, the principal driver that
decreases critical mass of organ function [64], we also believe
stem cell repair mechanisms that reduce the development of
healthy tissue into fibrotic tissue should be prioritized.
Therefore, recent discoveries which implicate MSC mecha-
nistic pathways that involve the expansion of T-regs seem
promising as this regulatory arm of immunity targets early
inflammatory events that potentially lead to fibrosis.
In addition, stem cell use as an IR-organ treatment requires
comprehensive profiling to understand and minimize potential
risks before clinical use. Clinical considerations also include
but are not limited to the route, dosage, and timing of admin-
istration. Injecting adipose-derived stromal vascular fractions
prior to ischemia in a rat model of renal IRI demonstrated
more ameliorative properties and significantly reduced
tubulointerstitial fibrosis than when injected post-ischemia
[65]. However, the clinical nature of transplantation may pro-
vide greater freedom in choosing exactly when to administer
the regenerative therapy compared to other indications. The
route of administration should also not be overlooked, as
many studies have shown that MSCs injected into the venous
system often become trapped in the microvasculature of the
lungs [18, 66]. Compared to systemic arterial or venous injec-
tion of stem cell therapies, studies have found that direct MSC
injection (in this case into the renal artery in a renal model of
IRI) has the most profound effect on the injured organ and also
required much lower doses [67]. Direct intraparenchymal or
intra/subcapsular routes have also been utilized in stem cell
renal IR research as direct renal artery injection can be asso-
ciated with renal microvasculature occlusion at higher thera-
peutic doses. The nature of solid organ transplantation, howev-
er, may actually allow beneficial flexibility in the choice of
administration route since the organs vessels are at least tran-
siently accessible. The topical route of application to the liver in
a rat hepatic IRI model was also tested by Lam et al. with
promising effects [68]. Lastly, the clinical setting of administra-
tionmay also be important.MSCsmay be altered by commonly
used anesthetic agents as highlighted in a recent rat model of
hepatic IRI. Intravenously administered dexmedetomidine and
midazolam enhanced the protective effects of MSC during liver
IRImore effectively than propofol by binding toMSC receptors
and regulating a downstream paracrine effect [69•].
Collectively, this is a reminder that other manipulations during
organ repair could also have an opposing effect on MSC regen-
erative properties, thus reducing their potential benefits.
In the future, the increasing accessibility of ex vivo perfu-
sion technologies [70, 71] may provide an ideal setting to
address the many remaining questions around stem cell
therapy’s role in preventing peri-transplant injury and provide
the bridge to translating its undoubted potential into real pa-
tient benefit.
Curr Transpl Rep (2019) 6:146–154 151
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflict of
interest.
Human and Animal Rights and Informed Consent This article does not
contain any studies with human or animal subjects performed by any of
the authors.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Levitt M. Could the organ shortage ever be met? Life Sci Soc
Policy. 2015;11:6.
2. Saidi RF, Rajeshkumar B, Shariftabrizi A, Bogdanov AA, Zheng S,
Dresser K, et al. Human adipose-derived mesenchymal stem cells
attenuate liver ischemia-reperfusion injury and promote liver regen-
eration. Surgery. 2014;156:1225–31.
3. Braun H, Schmidt BM, Raiss M, Baisantry A, Mircea-Constantin
D, Wang S, et al. Cellular senescence limits regenerative capacity
and allograft survival. J Am Soc Nephrol. 2012;23:1467–73.
4. Port FK, Bragg-Gresham JL, Metzger RA, Dykstra DM, Gillespie
BW, Young EW, et al. Donor characteristics associated with re-
duced graft survival: an approach to expanding the pool of kidney
donors. Transplantation. 2002;74:1281–6.
5. Zhao H, Alam A, Soo AP, George AJT, Ma D. Ischemia-
reperfusion injury reduces long term renal graft survival: mecha-
nism and beyond. EBioMedicine. 2018;28:31–42.
6. Bantounas I, Ranjzad P, Tengku F, Silajdzic E, Forster D, Asselin
MC, et al. Generation of functioning nephrons by implanting hu-
man pluripotent stem cell-derived kidney progenitors. Stem Cell
Rep. 2018;10:766–79.
7. Raven A, Lu WY, Man TY, Ferreira-Gonzalez S, O'Duibhir E,
Dwyer BJ, et al. Cholangiocytes act as facultative liver stem cells
during impaired hepatocyte regeneration. Nature. 2017;547:350–4.
8. De Filippo RE, Kornitzer BS, Yoo JJ, Atala A. Penile urethra re-
placement with autologous cell-seeded tubularized collagen matri-
ces. J Tissue Eng Regen Med. 2015;9:257–64.
9. Taylor DA, Frazier OH, Elgalad A, Hochman-Mendez C, Sampaio
LC. Building a Total bioartificial heart: harnessing nature to over-
come the current hurdles. Artif Organs. 2018;42:970–82.
10. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C.
Administered mesenchymal stem cells protect against ischemic
acute renal failure through differentiation-independent mecha-
nisms. Am J Physiol Renal Physiol. 2005;289:F31–42.
11. Lange C, Tögel F, Ittrich H, Clayton F, Nolte-Ernsting C, Zander
AR, et al. Administered mesenchymal stem cells enhance recovery
from ischemia/reperfusion-induced acute renal failure in rats.
Kidney Int. 2005;68:1613–7.
12. Sadek E, Afifi NM, Elfattah L, Mohsen MAA. Histological study
on effect of mesenchymal stem cell therapy on experimental renal
injury induced by ischemia/reperfusion in male albino rat. Int J
Stem Cells. 2013;6:55–66.
13. Feng Z, Ting J, Alfonso Z, StremBM, Fraser JK, Rutenberg J, et al.
Fresh and cryopreserved, uncultured adipose tissue-derived stem
and regenerative cells ameliorate ischemia-reperfusion-induced
acute kidney injury. Nephrol Dial Transplant. 2010;25:3874–84.
14. Wang XW, Zhou S, Obulkasim Y, Zhang H, Dai Z, Zhu B, et al.
BM-MSCs protect against liver ischemia/reperfusion injury via
HO-1 mediated autophagy. Mol Med Rep. 2018;2:2253–62.
15. LimM,WangW, Liang L, Han ZB, Li Z, Geng J, et al. Intravenous
injection of allogeneic umbilical cord-derived multipotent mesen-
chymal stromal cells reduces the infarct area and ameliorates cardi-
ac function in a porcine model of acute myocardial infarction. Stem
Cell Res Ther. 2018;9:129.
16. Nagahama H, Nakazaki M, Sasaki M, Kataoka-Sasaki Y, Namioka
T, Namioka A, et al. Preservation of interhemispheric cortical con-
nections through corpus callosum following intravenous infusion of
mesenchymal stem cells in a rat model of cerebral infarction. Brain
Res. 2018;1695:37–44.
17.• Chouchani ET, Pell VR, Gaude E, Aksentijevic D, Sundier SY,
Robb EL, et al. Ischaemic accumulation of succinate controls re-
perfusion injury through mitochondrial ROS. Nature. 2014;515:
431–5. This metabolomics study demonstrates that a princial
driver of ROS formation in ischaemia reperfusion injury in a
range of tissues is due to the ischemic accumulation of succinate
and its rapid re-oxidation by succinate dehydrogenase during
reperfusion. Chemical inhibition of succinate accumulationwas
shown to decrease infart size in an IRI heart mouse model, and
improves neurological scoring in an IRI brain mouse model.
18. Leibacher J, Henschler R. Biodistribution, migration and homing of
systemically applied mesenchymal stem/stromal cells. Stem Cell
Res Ther. 2016;7:7.
19. Sosa RA, Zarrinpar A, Rossetti M, Lassman CR, Naini BV, Datta
N, et al. Early cytokine signatures of ischemia/reperfusion injury in
human orthotopic liver transplantation. JCI Insight. 2016;1:e89679.
20. Qiao PF, Yao L, Zhang XC, Li GD, Wu DQ. Heat shock pretreat-
ment improves stem cell repair following ischemia-reperfusion in-
jury via autophagy. World J Gastroenterol. 2015;21:12822–34.
21. Xu Y, Shi T, Xu A, Zhang L. 3D spheroid culture enhances survival
and therapeutic capacities of MSCs injected into ischemic kidney. J
Cell Mol Med. 2016;20:1203–13.
22. Zhao X, Qiu X, Zhang Y, Zhang S, Gu X, Guo H. Three-
dimensional aggregates enhance the therapeutic effects of adipose
mesenchymal stem cells for ischemia-reperfusion induced kidney
injury in rats. Stem Cells Int. 2016;2016:9062638.
23.•• Bai M, Zhang L, Fu B, Bai J, Zhang Y, Cai G, et al. IL-17A
improves the efficacy of mesenchymal stem cells in ischemic-
reperfusion renal injury by increasing Treg percentages by the
COX-2/PGE2 pathway. Kidney Int. 2018;93:814–25. This study
indicates an important in vivo role for T-regs in IR repair and
its upregulation through the COX2/PGE2 pathway.
24. Baratelli F, Lin Y, Zhu L, Yang S, Heuzé-Vourc’h N, Zeng G, et al.
Prostaglandin E2 Induces FOXP3 Gene Expression and T
Regulatory Cell Function in Human CD4. J Immunol. 2005;175:
1483–90.
25.• Sivanathan KN, Rojas-Canales DM, Hope CM, Krishnan R,
Carroll RP, Gronthos S, et al. Interleukin-17A-induced humanmes-
enchymal stem cells are superior modulators of immunological
function. Stem Cells. 2015;33:2850–63. This research reinforces
the importance of T-regs in IR repair and the promising utility
of bone-derived MSCs cultured with IL-17A in IR therapy.
Pretreatment encouraged induction of T-regs and supressed
TGF-b1 secretion better than non-pretreated MSCs, and with
minimal immunogenecity associated with MHC upregulation.
152 Curr Transpl Rep (2019) 6:146–154
26. Thomson. Embryonic stem cell lines derived from human blasto-
cysts. Science. 1998;282:1145–7.
27. Mori da Cunha MG, Zia S, Beckmann DV, Carlon MS, Arcolino
FO, Albersen M, et al. Vascular endothelial growth factor up-
regulation in human amniotic fluid stem cell enhances
Nephroprotection after ischemia-reperfusion injury in the rat. Crit
Care Med. 2017;45:e86–96.
28. Liu N, Wang H, Han G, Cheng J, Hu W, Zhang J. Enhanced pro-
liferation and differentiation of HO-1 gene-modified bone marrow-
derived mesenchymal stem cells in the acute injured kidney. Int J
Mol Med. 2018;42:946–56.
29. Morigi MI, Imberti M, Corna B, Abbate D, Rota M, Rottoli C, et al.
Human bone marrow mesenchymal stem cells accelerate recovery
of acute renal injury and prolong survival in mice. Stem Cells.
2008;26:2075–82.
30. Giordano A, Galderisi U, Marino IR. From the laboratory bench to
the patient's bedside: an update on clinical trials with mesenchymal
stem cells. J Cell Physiol. 2007;211:27–35.
31.•• Zhu F, Lee Shin O, Pei G, Hu Z, Yang J, Zhu H, et al. Adipose-
derived mesenchymal stem cells employed exosomes to attenuate
AKI-CKD transition through tubular epithelial cell dependent Sox9
activation. Oncotarget. 2017;8:70707–26. Zhu et al. demonstrated
the importance of MSC-derived exosomes and of transcription
factor, Sox9 in mitigating IR repair. Human adipose derived
MSCs were found to promote tubule regeneration, but the effect
was inhibited by removing either exosomes or by downregulating
Sox9 expression in MSC treated renal IRI mice.
32. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master
regulator of fibrosis. Nat Rev Nephrol. 2016;12:325–38.
33. Jo A, Denduluri S, Zhang B, Wang Z, Yin L, Yan Z, et al. The
versatile functions of Sox9 in development, stem cells, and human
diseases. Genes Dis. 2014;1:149–61.
34. Bennett MR, Czech KA, Arend LJ, Witte DP, Devarajan P, Potter
SS. Laser capture microdissection-microarray analysis of focal seg-
mental glomerulosclerosis glomeruli. Nephron Exp Nephrol.
2007;107:e30–40.
35. WangW, Du Z, Yan J, Ma D, Shi M, ZhangM, et al. Mesenchymal
stem cells promote liver regeneration and prolong survival in small-
for-size liver grafts: involvement of C-JunN-terminal kinase, cyclin
D1, and NF-kappaB. PLoS One. 2014;9:e112532.
36. Belizario J, Vieira-Cordeiro L, Enns S. Necroptotic cell death sig-
naling and execution pathway: lessons from knockout mice.Mediat
Inflamm. 2015;2015:128076.
37. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflam-
mation. Nature. 2015;517:311–20.
38. Jin ZQ, Karliner JS, Vessey DA. Ischaemic postconditioning pro-
tects isolated mouse hearts against ischaemia/reperfusion injury via
sphingosine kinase isoform-1 activation. Cardiovasc Res. 2008;79:
134–40.
39. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-
phosphate signaling and its role in disease. Trends Cell Biol.
2012;22:50–60.
40.•• Yuan X, Li D, Chen X, Han C, Xu L, Huang T, et al. Extracellular
vesicles from human-induced pluripotent stem cell-derived mesen-
chymal stromal cells (hiPSC-MSCs) protect against renal ischemia/
reperfusion injury via delivering specificity protein (SP1) and tran-
scriptional activating of sphingosine kinase 1 and inhibiting
necroptosis. Cell Death Dis. 2017;8:3200. Study indicates the role
of extracellular vesicle transfer and delivery of transcription
factors specifically to IR renal tissue and how it modulates sig-
nalling to prevent necroptosis.
41. Man K, Ng KT, Lee TK, Lo CM, Sun CK, Li XL, et al. FTY720
attenuates hepatic ischemia-reperfusion injury in normal and cir-
rhotic livers. Am J Transplant. 2005;5:40–9.
42. Qi S, Wu D. Bone marrow-derived mesenchymal stem cells protect
against cisplatin-induced acute kidney injury in rats by inhibiting
cell apoptosis. Int J Mol Med. 2013;32:1262–72.
43. Gonzalez-Rey E, Gonzalez MA, Varela N, O’Valle F, Hernandez-
Cortes P, Rico L, et al. Human adipose-derived mesenchymal stem
cells reduce inflammatory and T cell responses and induce regula-
tory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis.
2010;69:241–8.
44. Hu J, Zhang L, Wang N, Ding R, Cui S, Zhu F, et al. Mesenchymal
stem cells attenuate ischemic acute kidney injury by inducing reg-
ulatory T cells through splenocyte interactions. Kidney Int.
2013;84:521–31.
45. Sun P, Liu J, Li W, Xu X, Gu X, Li H, et al. Human endometrial
regenerative cells attenuate renal ischemia reperfusion injury in
mice. J Transl Med. 2016;14:28.
46. Romano M, Tung SL, Smyth LA, Lombardi G. Treg therapy in
transplantation: a general overview. Transpl Int. 2017;30:745–53.
47. Vignali DAA, Collison LW, Workman CJ. How regulatory T cells
work. Nat Rev Immunol. 2008;8:523–32.
48.•• Shen B, Liu J, Zhang F, Wang Y, Qin Y, Zhou Z, et al. CCR2
positive exosome released by mesenchymal stem cells suppresses
macrophage functions and alleviates ischemia/reperfusion-induced
renal injury. Stem Cells Int. 2016;2016:1240301. This study dem-
onstrates that exosomal transfer of chemokine receptors and
not only exosomal transfer of transcription factors or interfer-
ing RNAs can play a significant role in IR organ repair.
49. Tang M, Zhang K, Li Y, He QH, Li GQ, Zheng QY, et al.
Mesenchymal stem cells alleviate acute kidney injury by down-
regulating C5a/C5aR pathway activation. Int Urol Nephrol.
2018;50:1545–53.
50. Bi LY, Zhao DA, Yang DS, Guo JG, Liang B, Zhang RX, et al.
Effects of autologous SCF- and G-CSF-mobilized bone marrow
stem cells on hypoxia-inducible factor-1 in rats with ischemia-
reperfusion renal injury. Genet Mol Res. 2015;14:4102–12.
51. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recom-
binant human bonemorphogenetic protein-2 trials in spinal surgery:
emerging safety concerns and lessons learned. Spine J. 2011;11:
471–91.
52. Woolthuis CM, Mariani N, Verkaik-Schakel RN, Brouwers-Vos
AZ, Schuringa JJ, Vellenga E, et al. Aging impairs long-term he-
matopoietic regeneration after autologous stem cell transplantation.
Biol Blood Marrow Transplant. 2014;20:865–71.
53. Tan X, Yin R, Chen Y, Gao D, Zhang X. Postconditioning attenu-
ates renal ischemia-reperfusion injury bymobilization of stem cells.
J Nephrol. 2015;28:289–98.
54. Liu L, Yu Q, Lin J, Lai X, Cao W, Du K, et al. Hypoxia-inducible
factor-1alpha is essential for hypoxia-induced mesenchymal stem
cell mobilization into the peripheral blood. Stem Cells Dev.
2011;20:1961–71.
55. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N,
KleinmanME, et al. Progenitor cell trafficking is regulated by hyp-
oxic gradients through HIF-1 induction of SDF-1. Nat Med.
2004;10:858–64.
56. MacAllister R, Clayton T, Knight R, Robertson S, Nicholas J,
Motwani M, et al. In REmote preconditioning for Protection
Against Ischaemia-Reperfusion in renal transplantation
(REPAIR): a multicentre, multinational, double-blind, factorial de-
signed randomised controlled trial. Southampton; 2015.
57.• Oron U, Tuby H,Maltz L, Sagi-Assif O, Abu-Hamed R, Yaakobi T,
et al. Autologous bone-marrow stem cells stimulation reverses post-
ischemic-reperfusion kidney injury in rats. Am J Nephrol. 2014;40:
425–33.This article posits an innovative manipulation of the IR
injured by endogenous stem cell mobilization with low-level
laser therapy.
Curr Transpl Rep (2019) 6:146–154 153
58. Han Z, Jing Y, Zhang S, Liu Y, Shi Y, Wei L. The role of immuno-
suppression of mesenchymal stem cells in tissue repair and tumor
growth. Cell Biosci. 2012;2:8.
59. Torres Crigna A, Daniele C, Gamez C,Medina Balbuena S, Pastene
DO, Nardozi D, et al. Stem/stromal cells for treatment of kidney
injuries with focus on preclinical models. Front Med (Lausanne).
2018;5:179.
60. Caplan AI. Why are MSCs therapeutic? New data: new insight. J
Pathol. 2009;217:318–24.
61. Fraser J, Wulur I, Alfonso Z, Zhu M, Wheeler E. Differences in
stem and progenitor cell yield in different subcutaneous adipose
tissue depots. Cytotherapy. 2007;9:459–67.
62. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu
M, et al. Comparison of multi-lineage cells from human adipose
tissue and bone marrow. Cells Tissues Organs. 2003;174:101–9.
63. Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, Munoz-Lopez M,
Real PJ, Macia A, et al. Human induced pluripotent stem cells
develop teratomamore efficiently and faster than human embryonic
stem cells regardless the site of injection. Stem Cells. 2010;28:
1568–70.
64. Mannon RB. Therapeutic targets in the treatment of allograft fibro-
sis. Am J Transplant. 2006;6:867–75.
65. Zhou L, Xu L, Shen J, Song Q, Wu R, Ge Y, et al. Preischemic
administration of nonexpanded adipose stromal vascular fraction
attenuates acute renal ischemia/reperfusion injury and fibrosis.
Stem Cells Transl Med. 2016;5:1277–88.
66. Kurtz A.Mesenchymal stem cell delivery routes and fate. Int J Stem
Cells. 2008;1:1–7.
67. Cai J, Yu X, Xu R, Fang Y, Qian X, Liu S, et al. Maximum efficacy
of mesenchymal stem cells in rat model of renal ischemia-
reperfusion injury: renal artery administration with optimal num-
bers. PLoS One. 2014;9:e92347.
68. Lam PK, Chong CCN, Lo AWI, Chan AWH, Tong CSW, Chin
DWC, et al. Topical application of mesenchymal stromal cells ame-
liorated liver parenchyma damage after ischemia-reperfusion injury
in an animal model. Transplant Direct. 2017;3:e160.
69.• Feng J, Yao W, Zhang Y, Xiang AP, Yuan D, Hei Z. Intravenous
anesthetics enhance the ability of human bone marrow-derived
mesenchymal stem cells to alleviate hepatic ischemia-reperfusion
injury in a receptor-dependent manner. Cell Physiol Biochem.
2018;47:556–66. Study suggests complications of stem cell IR
organ therapy when translated to the clinical setting by dem-
onstrating an anesthetic-induced effect on bone marrow-
derived MSCs.
70. Nasralla D, Coussios CC, Mergental H, Akhtar MZ, Butler AJ,
Ceresa CDL, et al. A randomized trial of normothermic preserva-
tion in liver transplantation. Nature. 2018;557:50–6.
71. DiRito JR, Hosgood SA, Tietjen GT, Nicholson ML. The future of
marginal kidney repair in the context of normothermic machine
perfusion. Am J Transplant. 2018;18:2400–8.
Publisher’s Note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
154 Curr Transpl Rep (2019) 6:146–154
